The insulin-like growth factor 1 receptor in cancer: Old focus, new future

被引：144

作者：

Hartog, Hermien

Wesseling, Jelle

Boezen, H. Marike

van der Graaf, Winette T. A.

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Univ Groningen, Med Ctr, Dept Oncol, Groningen, Netherlands

[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands

[4] Univ Groningen, Med Ctr, Dept Epidemiol, Groningen, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2007年 / 43卷 / 13期

关键词：

insulin-like growth factor 1 receptor; insulin receptor; hybrid receptor; tyrosine kinase inhibitors; targeted therapy; growth factor receptor; antibody; cancer;

D O I：

10.1016/j.ejca.2007.05.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The importance of insulin-like growth factor I receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases 1 and 11 clinical trials. interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1895 / 1904

页数：10

共 106 条

[101] Interaction of IGF signaling and the androgen receptor in prostate cancer progression [J].